Literature DB >> 6824712

Biochemical studies in Niemann-Pick disease. I. Major sphingolipids of liver and spleen.

M T Vanier.   

Abstract

In liver and spleen specimens of 12 patients with Niemann-Pick disease types A or B, sphingomyelin was increased 15-45-fold, total phospholipids 4-10-fold and cholesterol 3-6-fold over the normal values. The storage pattern was qualitatively similar in both types but the degree of accumulation was less in type B. In Niemann-Pick disease type C (16 cases), sphingomyelin was increased 3.5-fold in liver and 6-fold in spleen. In all forms of Niemann-Pick disease, bis(monoacylglycero)phosphate was markedly elevated. Glycosphingolipids were studied in six cases with type C, three cases with type B and two cases with type A. Glucosylceramide showed the largest increase from the normal pattern in all types of Niemann-Pick disease. Highest values were recorded in type C, 14- and 35-fold normal concentrations in liver and spleen, respectively. Other neutral glycosphingolipids, particularly lactosylceramide, were also elevated, and a 2-4-fold increase of ganglioside GM3 occurred. The fatty acid profiles of the sphingolipids showed only minor alterations. In contrast to the largely dominating sphingomyelin storage found in liver and spleen of Niemann-Pick disease types A and B, the major characteristic of the lipid storage in Niemann-Pick disease type C was the absence of any prevailing accumulation and, thus, the concept of this disorder as a primary sphingomyelin storage disease is not founded.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6824712     DOI: 10.1016/0005-2760(83)90218-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  58 in total

Review 1.  Lipid changes in Niemann-Pick disease type C brain: personal experience and review of the literature.

Authors:  M T Vanier
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

2.  Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease.

Authors:  Forbes D Porter; David E Scherrer; Michael H Lanier; S Joshua Langmade; Vasumathi Molugu; Sarah E Gale; Dana Olzeski; Rohini Sidhu; Dennis J Dietzen; Rao Fu; Christopher A Wassif; Nicole M Yanjanin; Steven P Marso; John House; Charles Vite; Jean E Schaffer; Daniel S Ory
Journal:  Sci Transl Med       Date:  2010-11-03       Impact factor: 17.956

3.  Deposition of lipopigment--a new feature of human splenic sinus endothelium (SSE). Ultrastructural and histochemical study.

Authors:  M Elleder
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

4.  Membrane lipids regulate ganglioside GM2 catabolism and GM2 activator protein activity.

Authors:  Susi Anheuser; Bernadette Breiden; Günter Schwarzmann; Konrad Sandhoff
Journal:  J Lipid Res       Date:  2015-07-14       Impact factor: 5.922

5.  Metabolic abnormalities in feline Niemann-Pick type C heterozygotes.

Authors:  D E Brown; M A Thrall; S U Walkley; S Wurzelmann; D A Wenger; R W Allison; C A Just
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

6.  [International Children's Day].

Authors: 
Journal:  Pediatriia       Date:  1977-06

7.  Niemann-Pick disease type C with enhanced glycolipid storage. Report on further case of so-called lactosylceramidosis.

Authors:  M Elleder; A Jirásek; F Smíd; J Ledvinová; G T Besley; M Stopeková
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

8.  Fetal Niemann-Pick disease type C: ultrastructural and lipid findings in liver and spleen.

Authors:  C Dumontel; C Girod; F Dijoud; Y Dumez; M T Vanier
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

9.  Niemann-Pick disease type C. Study on the nature of the cerebral storage process.

Authors:  M Elleder; A Jirásek; F Smíd; J Ledvinová; G T Besley
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

10.  New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat.

Authors:  James E Wraith; Jackie Imrie
Journal:  Ther Clin Risk Manag       Date:  2009-11-18       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.